| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | USV chided by FDA over contamination risks at India site | ||
| Di | AriBio's oral Alzheimer's drug meets monotherapy goal in phase 3 as Fosun weighs licensing option | ||
| Mo | Leo Pharma IPO plans stalled by market volatility: Bloomberg | ||
| Mo | Eisai, Linus Health launch 'brain health' digital resource | ||
| Mo | With Klygefa approvals, AZ expands myasthenia gravis domain beyond Soliris, Ultomiris | ||
| Mo | Roche's Gazyva adds 3rd immune indication with first FDA nod for primary membranous nephropathy | ||
| Mo | 2026's Fiercest Women in Life Sciences | ||
| So | FDA rejects Summit's ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class | ||
| So | Genentech brings every day wins to life in patient-focused Hemlibra push | ||
| Sa | The Oral GLP-1 Tracker: Foundayo, Wegovy pill keep scripts on the ascent | ||
| 13.11. | Measurement Everywhere: Why the Future Can't Be Measured in the Rearview Mirror | ||
| 13.11. | Europe's CHMP backs Baxfendy, gives Hansoh's Aumseqa another chance | ||
| 13.11. | Teva CEO 'proud' of pipeline buzz as innovative-generics hybrid rolls out 1st R&D day | ||
| 13.11. | Bavarian Nordic C-suite stability in question as CFO steps down amid Q3 beat | ||
| 13.11. | Fierce Pharma Asia-China's Big Pharma ambition; Treasury's China crackdown; Takeda's narcolepsy launch | ||
| 13.11. | Sanofi teams with British comic Beano for Type 1 diabetes education push | ||
| 13.11. | Novo amps up Wegovy marketing with DJ Khaled spinning his weight-loss tale | ||
| 12.11. | Pharmas should stay agile as Democrats amp up scrutiny over Trump's MFN deals | ||
| 12.11. | FDA appears to pause controversial speedy review program, complete response letter disclosures | ||
| 12.11. | Orzeyful's 'lighter' DEA schedule paves way for Takeda's first-in-class narcolepsy launch | ||
| 12.11. | Radiopharma player PharmaLogic snaps up Lantheus' CDMO business, plant as Curium acquisition advances | ||
| 12.11. | AI models from Google, Anthropic and more lean on recommending promoted drugs: study | ||
| 11.11. | FDA cites record request breakdowns in trio of warning letters to API makers | ||
| 11.11. | Legend Biotech shares fall 16% after first earnings report under new CEO | ||
| 11.11. | BioNTech pays $205M for FDA voucher to speed up 'late-stage oncology pipeline' |